Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRDM14-siRNA
- Development stage
- Preclinical
- Lead developer
- ARIZ Precision Medicine
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
ARIZ Precision Medicine is developing a siRNA-based therapeutic targeting PRDM14 for the treatment of breast cancer, including triple-negative breast cancer (TNBC). PRDM14 (PRDI-BF1 and RIZ domain zinc finger protein 14) is an epigenetic regulator and transcription factor that is overexpressed in approximately 60% of breast cancers. Its overexpression is associated with the acquisition of cancer stem cell-like properties, chemoresistance, and increased metastatic potential. The therapeutic candidate utilizes small interfering RNA (siRNA) to silence the expression of the PRDM14 gene. This siRNA is delivered using ARIZ's proprietary Targeted Nanoparticle Drug Delivery System (T-DDS), which is designed to specifically target cancer cells while minimizing off-target effects. By knocking down PRDM14, the therapy aims to inhibit tumor proliferation and restore sensitivity to conventional treatments.
- Other names
- Breast Cancer ProgramPRDM14-targeting siRNAPRDM-14-targeting siRNAPRDM 14-targeting siRNA
02
Targets
KMT (Histone-lysine methyltransferases)
Beyond the preview
Go deeper on PRDM14-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRDM14-siRNA.